AR095443A1 - Heterociclos condensados con acción sobre atr - Google Patents
Heterociclos condensados con acción sobre atrInfo
- Publication number
- AR095443A1 AR095443A1 ARP140100990A ARP140100990A AR095443A1 AR 095443 A1 AR095443 A1 AR 095443A1 AR P140100990 A ARP140100990 A AR P140100990A AR P140100990 A ARP140100990 A AR P140100990A AR 095443 A1 AR095443 A1 AR 095443A1
- Authority
- AR
- Argentina
- Prior art keywords
- cycloalkyl
- aryl
- ring
- heteroaryl
- mono
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
Reivindicación 1: Una entidad química seleccionada de los compuestos de fórmula (1) en donde R¹ se selecciona de arilo o heteroarilo; R² se selecciona de NR³SO₂R³, alquilo, cicloalquilo, arilo y heteroarilo; en donde R³ se selecciona independientemente en cada caso de H, alquilo opcionalmente sustituido con 1, 2 ó 3 átomos de halo, cicloalquilo opcionalmente sustituido con 1, 2 ó 3 átomos de halo y heterocicloalquilo opcionalmente sustituido con 1, 2 ó 3 átomos de halo; y m es 1 ó 2; alquilo es un hidrocarburo saturado lineal que tiene hasta 10 átomos de carbono C₁₋₁₀ o un hidrocarburo saturado ramificado de entre 3 y 10 átomos de carbono C₃₋₁₀; cicloalquilo es un hidrocarburo C₃₋₁₀ saturado mono- o bi-cíclico, que puede estar opcionalmente fusionado a un grupo arilo; o cicloalquilo es adamantilo; heterocicloalquilo es un anillo C-ligado o N-ligado, de 3 - 10 miembros, saturado, mono- o bi-cíclico, que contiene 1, 2, 3 ó 4 heteroátomos anulares seleccionados independientemente de N, S y O, en donde un átomo de N o S en el anillo puede ser sustituido con oxígeno para formar un grupo N-óxido, sulfóxido o sulfona; arilo es fenilo, bifenilo o naftilo; y heteroarilo es un anillo aromático mono-, bi- o tri-cíclico de 5, 6, 9 ó 10, 12, 13 ó 14 miembros, que puede contener 1, 2, 3 ó 4 heteroátomos anulares seleccionados independientemente de N, S y O; y sales, solvatos y estereoisómeros farmacéuticamente aceptables de dichos compuestos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13382089 | 2013-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR095443A1 true AR095443A1 (es) | 2015-10-14 |
Family
ID=48013903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140100990A AR095443A1 (es) | 2013-03-15 | 2014-03-13 | Heterociclos condensados con acción sobre atr |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US9453031B2 (es) |
| EP (1) | EP2970332B1 (es) |
| JP (1) | JP6379115B2 (es) |
| KR (1) | KR102206318B1 (es) |
| CN (1) | CN105051047B (es) |
| AR (1) | AR095443A1 (es) |
| AU (1) | AU2014229735B2 (es) |
| BR (1) | BR112015023060B1 (es) |
| CA (1) | CA2904768C (es) |
| CL (1) | CL2015002591A1 (es) |
| CY (1) | CY1120619T1 (es) |
| DK (1) | DK2970332T3 (es) |
| EA (1) | EA029771B1 (es) |
| ES (1) | ES2670674T3 (es) |
| HK (1) | HK1215021A1 (es) |
| HR (1) | HRP20180839T1 (es) |
| HU (1) | HUE037685T2 (es) |
| IL (1) | IL240708B (es) |
| LT (1) | LT2970332T (es) |
| MX (1) | MX368056B (es) |
| NO (1) | NO2970332T3 (es) |
| NZ (1) | NZ711038A (es) |
| PE (1) | PE20152007A1 (es) |
| PH (1) | PH12015502159B1 (es) |
| PL (1) | PL2970332T3 (es) |
| PT (1) | PT2970332T (es) |
| RS (1) | RS57216B1 (es) |
| SG (1) | SG11201507555PA (es) |
| SI (1) | SI2970332T1 (es) |
| TW (1) | TWI557131B (es) |
| UA (1) | UA118261C2 (es) |
| WO (1) | WO2014140644A1 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2897200C (en) | 2013-01-14 | 2021-07-06 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
| US9200004B2 (en) | 2013-01-15 | 2015-12-01 | Incyte Holdings Corporation | Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors |
| SG11201601259YA (en) | 2013-08-23 | 2016-03-30 | Incyte Corp | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors |
| US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| WO2016112374A2 (en) * | 2015-01-09 | 2016-07-14 | The General Hospital Corporation | Treating cancer using inhibitors of ataxia-telangiectasia mutated and rad3-related (atr) |
| WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
| TWI734699B (zh) | 2015-09-09 | 2021-08-01 | 美商英塞特公司 | Ｐｉｍ激酶抑制劑之鹽 |
| US9920032B2 (en) | 2015-10-02 | 2018-03-20 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| JP7025350B2 (ja) * | 2016-05-24 | 2022-02-24 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 三環式ヘテロシリック誘導体 |
| US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| EP3753937B1 (en) * | 2018-02-07 | 2024-01-10 | Wuxi Biocity Biopharmaceutics Co., Ltd. | Atr inhibitor and application thereof |
| WO2020094084A1 (zh) * | 2018-11-07 | 2020-05-14 | 南京明德新药研发有限公司 | 作为ret抑制剂的三并环衍生物 |
| CN113004303A (zh) * | 2019-12-18 | 2021-06-22 | 江苏恒瑞医药股份有限公司 | 嘧啶并噁嗪类三环衍生物、其制备方法及其在医药上的应用 |
| WO2021143821A1 (zh) * | 2020-01-17 | 2021-07-22 | 江苏恒瑞医药股份有限公司 | 稠合杂芳基类衍生物、其制备方法及其在医药上的应用 |
| KR20230088709A (ko) | 2020-10-16 | 2023-06-20 | 상하이 드 노보 파마테크 컴퍼니 리미티드 | 트리헤테로사이클릭 유도체, 이의 약학적 조성물 및 용도 |
| CN115466258A (zh) * | 2021-06-11 | 2022-12-13 | 成都苑东生物制药股份有限公司 | Atr抑制剂及其用途 |
| CN115286645A (zh) * | 2022-08-16 | 2022-11-04 | 南京雷正医药科技有限公司 | 三环杂环衍生物及其药物组合物和用途 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5583024A (en) | 1985-12-02 | 1996-12-10 | The Regents Of The University Of California | Recombinant expression of Coleoptera luciferase |
| EP0623125A1 (en) | 1992-01-15 | 1994-11-09 | E.I. Du Pont De Nemours And Company | Bridged heterocyclic fungicides |
| JPH08336393A (ja) | 1995-04-13 | 1996-12-24 | Mitsubishi Chem Corp | 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法 |
| DE69837529T2 (de) | 1997-02-12 | 2007-07-26 | Electrophoretics Ltd., Cobham | Proteinmarker für lungenkrebs und deren verwendung |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| US6602677B1 (en) | 1997-09-19 | 2003-08-05 | Promega Corporation | Thermostable luciferases and methods of production |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| PL205557B1 (pl) | 1999-02-10 | 2010-05-31 | Astrazeneca Ab | Pochodne indolu |
| NZ518028A (en) | 1999-11-05 | 2004-03-26 | Astrazeneca Ab | Quinazoline derivatives as VEGF inhibitors |
| ME00415B (me) | 2000-02-15 | 2011-10-10 | Pharmacia & Upjohn Co Llc | Pirol supstituisani 2-indol protein kinazni inhibitori |
| CN1431999A (zh) | 2000-05-31 | 2003-07-23 | 阿斯特拉曾尼卡有限公司 | 具有血管损伤活性的吲哚衍生物 |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| US20050277627A1 (en) | 2000-07-07 | 2005-12-15 | Arnould Jean C | Colchinol derivatives as vascular damaging agents |
| EP1301498A1 (en) | 2000-07-07 | 2003-04-16 | Angiogene Pharmaceuticals Limited | Colchinol derivatives as angiogenesis inhibitors |
| US8735411B2 (en) | 2006-10-02 | 2014-05-27 | Abbvie Inc. | Macrocyclic benzofused pyrimidine derivatives |
| RU2009120388A (ru) * | 2006-10-30 | 2010-12-10 | Новартис АГ (CH) | Имидазопиридазины в качестве ингибиторов липидкиназы |
| CA2684932A1 (en) * | 2007-05-09 | 2008-11-20 | Novartis Ag | Substituted imidazopyridazines as pi3k lipid kinase inhibitors |
| PL2467387T3 (pl) * | 2009-08-20 | 2015-08-31 | Karus Therapeutics Ltd | Tricykliczne związki heterocykliczne jako inhibitory kinazy 3-fosfoinozytydu |
| CN102020657A (zh) * | 2009-09-11 | 2011-04-20 | 上海艾力斯医药科技有限公司 | 稠合杂芳基衍生物、制备方法及其应用 |
| EP2585468A1 (en) * | 2010-06-23 | 2013-05-01 | Vertex Pharmaceuticals Incorporated | Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase |
| CN103313989B (zh) * | 2010-12-16 | 2016-05-04 | 霍夫曼-拉罗奇有限公司 | 三环pi3k抑制剂化合物和使用方法 |
-
2014
- 2014-03-13 AR ARP140100990A patent/AR095443A1/es unknown
- 2014-03-14 SG SG11201507555PA patent/SG11201507555PA/en unknown
- 2014-03-14 NO NO14716910A patent/NO2970332T3/no unknown
- 2014-03-14 UA UAA201510054A patent/UA118261C2/uk unknown
- 2014-03-14 WO PCT/GB2014/050825 patent/WO2014140644A1/en active Application Filing
- 2014-03-14 ES ES14716910.6T patent/ES2670674T3/es active Active
- 2014-03-14 MX MX2015011549A patent/MX368056B/es active IP Right Grant
- 2014-03-14 KR KR1020157025265A patent/KR102206318B1/ko active IP Right Grant
- 2014-03-14 TW TW103109396A patent/TWI557131B/zh active
- 2014-03-14 HU HUE14716910A patent/HUE037685T2/hu unknown
- 2014-03-14 LT LTEP14716910.6T patent/LT2970332T/lt unknown
- 2014-03-14 PE PE2015001900A patent/PE20152007A1/es active IP Right Grant
- 2014-03-14 PT PT147169106T patent/PT2970332T/pt unknown
- 2014-03-14 EP EP14716910.6A patent/EP2970332B1/en active Active
- 2014-03-14 CN CN201480015613.0A patent/CN105051047B/zh active Active
- 2014-03-14 EA EA201591781A patent/EA029771B1/ru not_active IP Right Cessation
- 2014-03-14 AU AU2014229735A patent/AU2014229735B2/en active Active
- 2014-03-14 US US14/774,294 patent/US9453031B2/en active Active
- 2014-03-14 JP JP2015562337A patent/JP6379115B2/ja active Active
- 2014-03-14 DK DK14716910.6T patent/DK2970332T3/en active
- 2014-03-14 PL PL14716910T patent/PL2970332T3/pl unknown
- 2014-03-14 SI SI201430698T patent/SI2970332T1/en unknown
- 2014-03-14 NZ NZ711038A patent/NZ711038A/en unknown
- 2014-03-14 RS RS20180576A patent/RS57216B1/sr unknown
- 2014-03-14 BR BR112015023060-1A patent/BR112015023060B1/pt active IP Right Grant
- 2014-03-14 CA CA2904768A patent/CA2904768C/en active Active
-
2015
- 2015-08-20 IL IL240708A patent/IL240708B/en active IP Right Grant
- 2015-09-10 CL CL2015002591A patent/CL2015002591A1/es unknown
- 2015-09-15 PH PH12015502159A patent/PH12015502159B1/en unknown
-
2016
- 2016-03-14 HK HK16102921.2A patent/HK1215021A1/zh unknown
-
2018
- 2018-05-24 CY CY181100555T patent/CY1120619T1/el unknown
- 2018-05-25 HR HRP20180839TT patent/HRP20180839T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR095443A1 (es) | Heterociclos condensados con acción sobre atr | |
| CL2016001287A1 (es) | Benzamidas sustituidas y procedimiento para su uso | |
| AR106798A1 (es) | Inhibidores pirazol de acc y usos de los mismos | |
| CY1119585T1 (el) | Ενωσεις τετραϋδροπυρρολοθειαζινης | |
| AR105459A1 (es) | Derivados de pirrolo[2,1-f][1,2,4]triazina útiles para tratar trastornos relacionados con kit y pdfgr | |
| AR106799A1 (es) | Inhibidores éster de acc y usos de los mismos | |
| CR20160099A (es) | Formulación de inhibidores de la syk | |
| AR105820A1 (es) | Análogos de nucleósidos sustituidos en el anillo aromático bicíclico 6-6 para su uso como inhibidores de prmt5 | |
| AR094309A1 (es) | Compuesto heterociclico fusionado y uso del mismo para el control de plagas | |
| AR093515A1 (es) | Triazolopirazinas | |
| AR090928A1 (es) | Compuestos de hexahidropirano[3,4-d][1,3]tiazin-2-amina heterociclicos sustituidos | |
| CR20150436A (es) | Nuevos octahidro-pirrolo[3,4-c]-pirrol y -piridina-fenilo | |
| ES2770058T3 (es) | Compuestos y composiciones destinados a modular las actividades de quinasa de EGFR mutante | |
| AR099995A1 (es) | Piridilamidinas fungicidas | |
| AR091273A1 (es) | Inhibidores de pirimidinil tirosina quinasa | |
| UY35485A (es) | Compuestos heterocíclicos y usos de los mismos | |
| AR100233A1 (es) | Composición de limpieza | |
| AR096684A1 (es) | Compuestos para tratar atrofia muscular espinal | |
| AR101690A1 (es) | Composiciones tensioactivas acuosas | |
| AR095426A1 (es) | Inhibidores tripeptídicos de la epoxicetona proteasa | |
| AR091519A1 (es) | Inhibidores pirrolopirazona de tanquirasa | |
| AR087311A1 (es) | Quinolinas sustituidas y su uso como medicamentos | |
| AR097866A1 (es) | Derivados de 4-azaindol | |
| AR094762A1 (es) | Compuestos de hexahidropirano[3,4-d][1,3]tiazin-2-amina sustituida con heteroarilo | |
| AR088805A1 (es) | 2-tiopirimidinonas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |